228 related articles for article (PubMed ID: 17031389)
1. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
[TBL] [Abstract][Full Text] [Related]
2. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
3. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
4. Assessment of drug-induced proarrhythmia: The importance of study design in the rabbit left ventricular wedge model.
Lu HR; Gallacher DJ; Yan GX
J Pharmacol Toxicol Methods; 2016; 81():151-60. PubMed ID: 27374776
[TBL] [Abstract][Full Text] [Related]
5. Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.
Farkas AS; Nattel S
Drugs; 2010 Mar; 70(5):573-603. PubMed ID: 20329805
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
7. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic.
Hondeghem LM; Carlsson L; Duker G
Circulation; 2001 Apr; 103(15):2004-13. PubMed ID: 11306531
[TBL] [Abstract][Full Text] [Related]
8. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
[TBL] [Abstract][Full Text] [Related]
9. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
10. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
11. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.
Valentin JP; Hoffmann P; De Clerck F; Hammond TG; Hondeghem L
J Pharmacol Toxicol Methods; 2004; 49(3):171-81. PubMed ID: 15172013
[TBL] [Abstract][Full Text] [Related]
12. Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Said TH; Wilson LD; Jeyaraj D; Fossa AA; Rosenbaum DS
J Cardiovasc Pharmacol; 2012 Aug; 60(2):165-71. PubMed ID: 22561361
[TBL] [Abstract][Full Text] [Related]
13. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
14. Preclinical electrophysiology assays of mitemcinal (GM-611), a novel prokinetic agent derived from erythromycin.
Kimura K; Tabo M; Itoh M; Mizoguchi K; Kato A; Suzuki M; Itoh Z; Omura S; Takanashi H
J Toxicol Sci; 2007 Aug; 32(3):217-30. PubMed ID: 17785939
[TBL] [Abstract][Full Text] [Related]
15. New in vitro model for proarrhythmia safety screening: IKs inhibition potentiates the QTc prolonging effect of IKr inhibitors in isolated guinea pig hearts.
Kui P; Orosz S; Takács H; Sarusi A; Csík N; Rárosi F; Csekő C; Varró A; Papp JG; Forster T; Farkas AS; Farkas A
J Pharmacol Toxicol Methods; 2016; 80():26-34. PubMed ID: 27063345
[TBL] [Abstract][Full Text] [Related]
16. Validation of a guinea pig Langendorff heart model for assessing potential cardiovascular liability of drug candidates.
Guo L; Dong Z; Guthrie H
J Pharmacol Toxicol Methods; 2009; 60(2):130-51. PubMed ID: 19616638
[TBL] [Abstract][Full Text] [Related]
17. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
18. Action potential experiments complete hERG assay and QT-interval measurements in cardiac preclinical studies.
Ducroq J; Printemps R; Guilbot S; Gardette J; Salvetat C; Le Grand M
J Pharmacol Toxicol Methods; 2007; 56(2):159-70. PubMed ID: 17604185
[TBL] [Abstract][Full Text] [Related]
19. Revisiting the hERG safety margin after 20 years of routine hERG screening.
Leishman DJ; Abernathy MM; Wang EB
J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
[TBL] [Abstract][Full Text] [Related]
20. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
